BioSpace News Archive

ŌNŌCOR LLC, a leader in endovascular safety technology, today announced it has received 510(k) U.S. Food and Drug Administration (FDA) clearance for its ŌNŌ retrieval system, the first major advance in endovascular bailout technology in decades.

XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a clinical stage pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce its participation in the H. C. Wainwright Global Investment Conference 2022, a hybrid in-person/ virtual conference being held May 23rd through 26th , 2022.

AbbVie (NYSE: ABBV) will participate in the Bernstein 38th Annual Strategic Decisions Conference on Wednesday, June 1, 2022.

Oak Hill Bio (“Oak Hill”), a clinical-stage neonatology and rare disease therapeutics company developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases, today announced that the Company sponsored a symposium at the 10th Annual International Conference on Clinical Neonatology that took place from May 21-23, 2022 in Turin, Italy.

Terremoto Biosciences today announced it has raised $75 million in a Series A financing.

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced that the Company has successfully completed a capital raise to support the Company’s R&D activities and improve its financial structure.

Endeavor BioMedicines , a clinical-stage biotechnology company targeting the core drivers of terminal diseases including oncology and fibrosis, today announced the first patient has been dosed in an open-label Phase 2 study evaluating ENV-101.

Helsinn Group announces the establishment of a new dedicated R&D hub at its U.S. subsidiary, Helsinn Therapeutics, Inc., that augments Helsinn Group’s global R&D organization.

MiNK Therapeutics , Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that its virtual-only Annual Meeting of Shareholders will be held at 5:00 PM ET on June 8, 2022.

Senti Biosciences, Inc. (Senti Bio), a leading gene circuit company, today announced the appointment of Kanya Rajangam, MD, PhD, as Chief Medical and Development Officer.